Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Einat B Vitner

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Human Molecular Genetics|July 10, 2010
Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidosesEinat B Vitner, Hani Dekel, Hila Zigdon, et al.
Acta Neuropathologica Communications|August 25, 2020
Innate immune response in neuronopathic forms of Gaucher disease confers resistance against viral-induced encephalitisSharon Melamed, Roy Avraham, Deborah E Rothbard, et al.
Pathogens (Basel, Switzerland)|April 3, 2021
Epitope Binning of Novel Monoclonal Anti F1 and Anti LcrV Antibodies and Their Application in a Simple, Short, HTRF Test for Clinical Plague DetectionAdva Mechaly, Einat B Vitner, Yinon Levy, et al.
The Journal of Biological Chemistry|February 27, 2021
Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virusEinat B Vitner, Hagit Achdout, Roy Avraham, et al.
Brain Communications|May 11, 2023
Antiviral activity of glucosylceramide synthase inhibitors in alphavirus infection of the central nervous systemRoy Avraham, Sharon Melamed, Hagit Achdout, et al.
Human Molecular Genetics|September 26, 2013
Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegenerationTamar Farfel-Becker, Einat B Vitner, Samuel L Kelly, et al.
Nature Medicine|January 21, 2014
RIPK3 as a potential therapeutic target for Gaucher's diseaseEinat B Vitner, Ran Salomon, Tamar Farfel-Becker, et al.
Journal of Neurochemistry|August 4, 2020
Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher diseaseShani Blumenreich, Chen Yaacobi, Ayelet Vardi, et al.
Advanced Materials (Deerfield Beach, Fla.)|April 14, 2024
Surface-Functionalized Microgels as Artificial Antigen-Presenting Cells to Regulate Expansion of T CellsJunzhe Lou, Charlotte Meyer, Einat B Vitner, et al.
Vaccines|February 15, 2019
Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus StrainsTomer Israely, Nir Paran, Noam Erez, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Human Molecular Genetics|July 10, 2010
Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidosesEinat B Vitner, Hani Dekel, Hila Zigdon, et al.
Acta Neuropathologica Communications|August 25, 2020
Innate immune response in neuronopathic forms of Gaucher disease confers resistance against viral-induced encephalitisSharon Melamed, Roy Avraham, Deborah E Rothbard, et al.
Pathogens (Basel, Switzerland)|April 3, 2021
Epitope Binning of Novel Monoclonal Anti F1 and Anti LcrV Antibodies and Their Application in a Simple, Short, HTRF Test for Clinical Plague DetectionAdva Mechaly, Einat B Vitner, Yinon Levy, et al.
The Journal of Biological Chemistry|February 27, 2021
Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virusEinat B Vitner, Hagit Achdout, Roy Avraham, et al.
Brain Communications|May 11, 2023
Antiviral activity of glucosylceramide synthase inhibitors in alphavirus infection of the central nervous systemRoy Avraham, Sharon Melamed, Hagit Achdout, et al.
Human Molecular Genetics|September 26, 2013
Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegenerationTamar Farfel-Becker, Einat B Vitner, Samuel L Kelly, et al.
Nature Medicine|January 21, 2014
RIPK3 as a potential therapeutic target for Gaucher's diseaseEinat B Vitner, Ran Salomon, Tamar Farfel-Becker, et al.
Journal of Neurochemistry|August 4, 2020
Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher diseaseShani Blumenreich, Chen Yaacobi, Ayelet Vardi, et al.
Advanced Materials (Deerfield Beach, Fla.)|April 14, 2024
Surface-Functionalized Microgels as Artificial Antigen-Presenting Cells to Regulate Expansion of T CellsJunzhe Lou, Charlotte Meyer, Einat B Vitner, et al.
Vaccines|February 15, 2019
Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus StrainsTomer Israely, Nir Paran, Noam Erez, et al.
Pageof 3